Carillon Tower Advisers Inc. bought a new stake in shares of Core Laboratories (NYSE:CLB) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 47,445 shares of the oil and gas company’s stock, valued at approximately $3,270,000.

Several other large investors have also bought and sold shares of CLB. JPMorgan Chase & Co. lifted its position in Core Laboratories by 4.3% in the third quarter. JPMorgan Chase & Co. now owns 1,306,668 shares of the oil and gas company’s stock valued at $151,352,000 after purchasing an additional 53,986 shares during the last quarter. AQR Capital Management LLC bought a new stake in Core Laboratories in the third quarter valued at approximately $230,000. Neuberger Berman Group LLC lifted its position in Core Laboratories by 18.0% in the third quarter. Neuberger Berman Group LLC now owns 544,227 shares of the oil and gas company’s stock valued at $63,038,000 after purchasing an additional 83,175 shares during the last quarter. Teachers Advisors LLC lifted its position in Core Laboratories by 28.6% in the third quarter. Teachers Advisors LLC now owns 3,377 shares of the oil and gas company’s stock valued at $391,000 after purchasing an additional 751 shares during the last quarter. Finally, Standard Life Aberdeen plc lifted its position in Core Laboratories by 27.1% in the third quarter. Standard Life Aberdeen plc now owns 9,500 shares of the oil and gas company’s stock valued at $1,100,000 after purchasing an additional 2,025 shares during the last quarter.

Several analysts have weighed in on CLB shares. Stifel Nicolaus set a $75.00 price objective on Core Laboratories and gave the company a “buy” rating in a research report on Friday, April 26th. Tudor Pickering raised Core Laboratories from a “hold” rating to a “buy” rating in a research note on Monday, February 25th. UBS Group set a $72.00 target price on Core Laboratories and gave the company a “hold” rating in a research note on Saturday, February 2nd. Finally, Zacks Investment Research raised Core Laboratories from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 17th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $86.45.

In related news, CAO Kevin Daniels sold 428 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $66.25, for a total value of $28,355.00. Following the sale, the chief accounting officer now directly owns 352 shares of the company’s stock, valued at $23,320. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 2.00% of the stock is owned by corporate insiders.

CLB opened at $55.80 on Thursday. The company has a debt-to-equity ratio of 1.92, a quick ratio of 1.45 and a current ratio of 1.84. Core Laboratories has a 52-week low of $54.18 and a 52-week high of $130.34. The company has a market cap of $2.44 billion, a PE ratio of 25.54, a price-to-earnings-growth ratio of 1.99 and a beta of 1.80.

Core Laboratories (NYSE:CLB) last posted its earnings results on Wednesday, April 24th. The oil and gas company reported $0.44 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.43 by $0.01. Core Laboratories had a return on equity of 57.13% and a net margin of 13.79%. The firm had revenue of $169.19 million for the quarter, compared to analysts’ expectations of $166.79 million. During the same period in the previous year, the firm earned $0.57 earnings per share. The business’s revenue was down .5% compared to the same quarter last year. As a group, equities analysts anticipate that Core Laboratories will post 1.99 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, May 21st. Investors of record on Friday, April 26th will be paid a $0.55 dividend. The ex-dividend date is Thursday, April 25th. This represents a $2.20 annualized dividend and a yield of 3.94%.

TRADEMARK VIOLATION NOTICE: “Carillon Tower Advisers Inc. Takes Position in Core Laboratories (CLB)” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2019/05/16/carillon-tower-advisers-inc-takes-position-in-core-laboratories-clb.html.

Core Laboratories Profile

Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. The company operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.

Recommended Story: How is an ETF different from a mutual fund?

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories (NYSE:CLB)

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.